Compare Becton Dickinson and Co (BDX) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs JPMorgan Chase & Co — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while JPMorgan Chase & Co trades at $362.07 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 19.5× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | JPM | |
|---|---|---|
Market Cap | $48.93B | $956.39B |
Sector | Health | Financials |
52-Week High | $185.39 | $362.04 |
52-Week Low | $138.62 | $282.84 |
Enterprise Value | $65.03B | — |
Dividend Yield | 2.34% | 1.67% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, near its pivot point of $359. The stock shows a bullish technical trend with moving averages supporting upside. Recent earnings beat expectations in Q1 and Q2 2026, with Q1 EPS of $5.94 versus $5.47 expected, though Q4 2025 missed. Revenue grew to $181.85B in 2025, and net income margin stands at 33.38%. A $1.50 dividend is scheduled for payment on July 31, 2026.
JPMorgan's outlook remains positive with analyst consensus at 'Moderate Buy' and a $374.18 price target, offering ~4% upside. Strong ROE of 18.43% and institutional accumulation highlight confidence. Risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI, as noted in recent news. The stock's valuation at P/E 15.42 is reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
